×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCGN – ocugen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/23
08:00 am
ocgn
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Low
Report
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
1/21
08:32 am
ocgn
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Medium
Report
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
1/20
08:02 am
ocgn
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Low
Report
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
1/16
12:56 pm
ocgn
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
Low
Report
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
1/15
07:02 pm
ocgn
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Medium
Report
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
1/15
08:15 am
ocgn
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
High
Report
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
1/13
12:41 pm
ocgn
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
Medium
Report
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
1/13
07:00 am
ocgn
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
Medium
Report
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
1/30
02:17 pm
ocgn
Form SCHEDULE 13G Ocugen, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G Ocugen, Inc. Filed by: VANGUARD GROUP INC
1/23
08:12 am
ocgn
Form 8-K Ocugen, Inc. For: Jan 22
Neutral
Report
Form 8-K Ocugen, Inc. For: Jan 22
1/21
05:29 pm
ocgn
Form 8-K Ocugen, Inc. For: Jan 20
Medium
Report
Form 8-K Ocugen, Inc. For: Jan 20
1/15
08:31 am
ocgn
Form 8-K Ocugen, Inc. For: Jan 15
High
Report
Form 8-K Ocugen, Inc. For: Jan 15
1/6
05:21 pm
ocgn
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Musunuri Shankar
Low
Report
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Musunuri Shankar
1/6
05:20 pm
ocgn
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Ramachandran Ramesh
Low
Report
Form 4 Ocugen, Inc. For: Jan 02 Filed by: Ramachandran Ramesh
12/18
05:17 pm
ocgn
Form 8-K Ocugen, Inc. For: Dec 12
Medium
Report
Form 8-K Ocugen, Inc. For: Dec 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/9
Ocugen Announces Share Repurchase Program
32.3%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
TOP News Decliners
9/30
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
-59.3%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: